Elevated circulating levels of CTRP1, a novel adipokine, in diabetic patients

Xin, Ya; Lyu, Xiaodong; Wang, Chongxian; Fu, Yanqin; Suhe, Zhang; Tian, Chenguang; Li, Qingju; Zhang, Dongming

doi:10.1507/endocrj.ej14-0016

Cited by 49 publications

(55 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased level of CTRP1 in our study can be interpreted as a compensatory mechanism for improving insulin resistance. In our study, we observed strong positive correlation between plasma level of CTRP1 and FBG and also HOMA-IR which was in consistent with previous reports in T2DM and MetS patients [15,20,33]. A growing body of evidence showed that hyperinsulinemia, as a hallmark of insulin resistance, led to de novo lipid synthesis and acceleration of lipid accumulation in liver.…”

Section: Discussionsupporting

confidence: 93%

Circulating Level of CTRP1 in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Is It through Insulin Resistance?

et al. 2015

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most common liver diseases. It is robustly linked to obesity and insulin resistance and is regarded as hepatic manifestation of metabolic syndrome (MetS). Adipokines are involved in the pathophysiology of liver diseases. The aim of this study was to evaluate the plasma concentrations of CTRP1 (complement-C1q TNF-related protein 1) in 22 patients with NAFLD, 22 patients with type 2 diabetes mellitus (T2DM), 22 patients with NAFLD+T2DM and 21 healthy controls, as well as their correlation with the level of metabolic and hepatic parameters. Plasma concentration of CTRP1 was measured with ELISA method. Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001). Moreover, we observed significant positive correlations between plasma level of CTRP1 and fasting blood glucose (FBG) (p<0.001), homeostasis model assessment of insulin resistance (HOMA-IR) (p<0.001), body mass index (BMI) (p = 0.001), alanine amino transferase (ALT) (p = 0.002), gamma glutamyl transferase (γ-GT) (p<0.001) and liver stiffness (LS) (p<0.001). Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD. Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.

show abstract

Section: Discussionsupporting

confidence: 93%

Circulating Level of CTRP1 in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Is It through Insulin Resistance?

et al. 2015

View full text Add to dashboard Cite

show abstract

“…C1q and tumour necrosis factor-related protein 1 (CTRP1) is a novel adipokine that is synthesized in arterial perivascular adipose tissue [5, 6]. Recent data suggest that high levels of circulating CTRP1 are associated with metabolic syndrome, adiponectin deficiency, platelet aggregation, athero-inflammation and hypertension [7-11]. …”

Section: Introductionmentioning

confidence: 99%

Association Between C1q/TNF-Related Protein-1 Levels in Human Plasma and Epicardial Adipose Tissues and Congestive Heart Failure

Yang¹,

Liu

Zhang

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: C1q and tumour necrosis factor-related protein 1 (CTRP1) possesses anti-atherogenic and anti-inflammatory effects. This study investigated whether the CTRP1 levels in the plasma and epicardial adipose tissue (EAT) were associated with congestive heart failure (CHF) and to disclose possible molecular mechanisms. Methods: Plasma and tissue samples were obtained from subjects with or without CHF. Plasma levels of CTRP1 were measured by ELISA. The mRNA levels of CTRP1 and inflammatory cytokines were detected by RT-PCR. The protein levels of CTRP1, aldosterone synthase (CYP11B2) and mitogen-activated protein kinase were examined by Western blotting. Results: The levels of CTRP1 in the plasma and EAT were higher in the CHF patients than those in the controls. There were no differences in the CTRP1 levels in cardiomyocytes between the CHF group and the non-CHF group. An exploratory survival analysis showed that higher CTRP1 values at admission were associated with a worse prognosis after discharge. CTRP1 increased the IL-6 mRNA level in H295R cells. CTRP1 recruited ERK1/2 and Jak-2 for aldosterone release by modulating the CYP11B2 protein level, and brain natriuretic peptide repressed the CTRP1-induced aldosterone release through the JAK2-STAT3 signalling pathways. Conclusion: The CTRP1 levels in the plasma and EAT were increased in the CHF patients. CTRP1 is involved in the pathogenesis of CHF by modulating IL-6 levels and aldosterone release.

show abstract

“…Serum CTRP1 levels were significantly increased in patients with T2DM [19,20] and plasma Aldosterone concentration is elevated in patients with diabetes mellitus [15]. Study group with diabetic nephropathy was selected because DN is associated with hypertension.…”

Section: Discussionmentioning

confidence: 99%